Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
186 articles with Protalix Biotherapeutics, Inc.
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Gamida Cell today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
Protalix BioTherapeutics believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion.
Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients With Ulcerative Colitis
The Company expects to report top-line results from this study by the end of March 2018.
Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation From the U.S. Food and Drug Administration
Fast Track designation highlights high unmet medical need in the treatment of Fabry disease.
Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients With Ulcerative Colitis
The phase II clinical trial is a randomized, open label, 2-arm study of OPRX-106 in patients with active mild to moderate ulcerative colitis.
The decision by the Commission confirms the opinion previously issued by the EMA Committee for Orphan Medicinal Products.
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients With Ulcerative Colitis
The Company expects to report top-line results from this study in the first quarter of 2018.
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference
Sixteen male and female adult patients were enrolled in the phase I/II clinical trial across three dosing cohorts (0.2 mg/kg, 1mg/kg and 2mg/kg) and received intravenous infusions of PRX-102 every two weeks.
11/27/2017Share prices for Protalix are up more than 3 percent this morning after the company reported positive results from its Phase I/II open label extension trial of pegunigalsidase alfa, PRX-102, for the treatment of Fabry disease.
Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union
In its official opinion letter, the COMP explained that Protalix has established that although satisfactory methods of treatment of Fabry disease have been authorized in the European Union, PRX-102 will be of significant benefit to those affected by Fabry disease.
The Company reported a net loss of $32.1 million, or $0.25 per share, basic and diluted, for the nine-month period ended September 30, 2017.
Protalix BioTherapeutics to Hold Third Quarter 2017 Financial Results and Corporate Update Conference Call on November 8, 2017
The company will provide a corporate update on Wednesday, November 8, 2017 at 8:30 am ET.
Protalix BioTherapeutics Enters into an Exclusive Ex-U.S. Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein.
Protalix To Hold Second Quarter 2017 Financial Results And Corporate Update Conference Call On August 9, 2017
Protalix Completes Private Note Exchange Of $9 Million Notes Maturing September 2018 For $8.55 Million Notes Maturing February 2022
Protalix Announces Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis Presented At The 40th European Cystic Fibrosis Society Conference
Protalix Announces Presentation Of Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis At The 40th European Cystic Fibrosis Society Conference
Protalix Announces FDA Investigational New Drug Clearance To Commence Once-Monthly Dosing Study Of Pegunigalsidase Alfa (PRX-102) For The Treatment Of Fabry Disease
Protalix Announces New Preclinical Results Demonstrating A Positive Effect Of Pegunigalsidase Alfa (PRX-102) On Small-Fiber Neuropathy In Fabry Disease Models Compared To Commercially Available Enzyme Replacement Therapies